LEO Pharma

137 articles about LEO Pharma

• LEO Pharma Release: New Study Investigating The Effect Of Low-Molecular-Weight Heparins On The Treatment Of Blood Clots In Cancer Patients

  8/19/2015

• LEO Pharma Supports The FDA's Selection Of Psoriasis As A Priority Disease

  8/4/2015

• LEO Pharma Announces New Vice President Of Sales

  7/6/2015

• LEO Pharma And Professional Football Player Jonathan Scott Partner To Increase Psoriasis Awareness

  6/8/2015

• arGEN-X, LEO Pharma Forge $116 Million Skin Pact

  5/22/2015

• Antares Pharma, Inc. Regains U.S. Marketing Rights To OTREXUP For Psoriasis Indication - Announces Termination Of LEO Pharma Marketing Agreement

  4/27/2015

• Fidelta Achieves Milestone In Collaboration With LEO Pharma

  3/3/2015

• LEO Pharma Announces New Drug Application Submission of the First Aerosol Foam for Plaque Psoriasis

  1/6/2015

• LEO Pharma Appoints Barbara Osborne As President & CEO Of LEO U.S. Region

  11/19/2014

• LEO Pharma And Japan Tobacco Enter Into License Agreement For Novel JAK inhibitor Drug Candidate

  11/4/2014

• LEO Pharma Announced New Taclonex® (Calcipotriene And Betamethasone Dipropionate) Topical Suspension, 0.005%/0.064% Indication For Treatment Of Scalp Plaque Psoriasis In Pediatric Patients Ages 12-17

  9/30/2014

• LEO Pharma & Klox Technologies Strike Global Dermatology Deal

  7/15/2014

• Antares Pharma, Inc. Receives Second Milestone Payment From LEO Pharma In OTREXUP Collaboration

  3/12/2014

• Antares Pharma, Inc. Announces LEO Pharma’s Launch Of OTREXUP (Methotrexate) Injection To Dermatologists For Adults With Psoriasis

  3/10/2014

• Antares Pharma, Inc. Enters Into An Exclusive U.S. Promotion And Marketing Agreement With LEO Pharma For OTREXUP™ In Dermatology

  11/14/2013

• LEO Pharma Expands QualityCare™ Patient Support Program

  10/28/2013

• LEO Pharma Puts Patients at the Heart of Innovation

  3/19/2013

• Virobay Inc. and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

  3/18/2013

• LEO Pharma Receives FDA Approval for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for Body Plaque Psoriasis

  10/26/2012

• LEO Pharma Initiates Global Search for New Partners

  6/14/2012